<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">tumors</journal-id><journal-title-group><journal-title xml:lang="ru">Malignant tumours</journal-title><trans-title-group xml:lang="en"><trans-title>Malignant tumours</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2224-5057</issn><issn pub-type="epub">2587-6813</issn><publisher><publisher-name>Rosoncoweb</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18027/2224-5057-2023-13-4-18-27</article-id><article-id custom-type="elpub" pub-id-type="custom">tumors-1274</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СОБСТВЕННЫЕ ИССЛЕДОВАНИЯ. ВОПРОСЫ ОНКОХИРУРГИИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>OWN RESEARCH. ONCOSURGERY ISSUES</subject></subj-group></article-categories><title-group><article-title>Метастазы в лимфатические узлы при однофокальном и мультифокальном папиллярном раке щитовидной железы на фоне аутоиммунного тиреоидита</article-title><trans-title-group xml:lang="en"><trans-title>Metastases to lymph nodes from monofocal and multifocal papillary thyroid malignant tumors in patients with autoimmune thyroiditis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рябченко</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ryabchenko</surname><given-names>Е. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Евгений В. Рябченко, к. м. н., заведующий хирургическим отделением №2, «Межтерриториальный центр эндокринной хирургии»</p><p>Краснодар;</p><p>доцент кафедры хирургии</p><p>Москва</p></bio><bio xml:lang="en"><p>Evgeny V. Ryabchenko, MD, PhD, Head of the Surgical Department No. 2 of the “Interterritorial Center for Endocrine Surgery”</p><p>Krasnodar;</p><p>Associate Professor of the Department of Surgery</p><p>Moscow</p></bio><email xlink:type="simple">rev7512@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ «Краснодарская Краевая клиническая больница №2», Минздрава Краснодарского края;&#13;
ФГАОУ ВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Krasnodar Regional Clinical Hospital No. 2;&#13;
Peoples’ Friendship University of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>15</day><month>01</month><year>2024</year></pub-date><volume>13</volume><issue>4</issue><fpage>18</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рябченко Е.В., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Рябченко Е.В.</copyright-holder><copyright-holder xml:lang="en">Ryabchenko Е.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.malignanttumors.org/jour/article/view/1274">https://www.malignanttumors.org/jour/article/view/1274</self-uri><abstract><p>Целью данного исследования было изучение факторов риска метастазирования в центральные и латеральные лимфатические узлы шеи при папиллярной карциноме щитовидной железы (ПКЩЖ) и мультифокальной папиллярной карциноме щитовидной железы (МПКЩЖ), особенно на фоне тиреоидита Хашимото (ТХ). Был проведен ретроспективный анализ 763 пациентов после тиреоидэктомии с двусторонней центральной лимфаденэктомией (ЦЛЭ) в межтерриториальном центре эндокринной хирургии г. Краснодара в период с октября 2011 по октябрь 2021 года. У всех пациентов были официальные гистологические подтверждения ТХ. Для выявления факторов риска метастазирования (Mts) в лимфатические узлы шеи был проведен многофакторный логистический регрессионный анализ. В нашем исследовании 277 пациентов с ПКЩЖ на фоне ТХ показало сравнительно низкие показатели Mts в центральные лимфатические узлы (ЦЛУ) по сравнению с пациентами с ПКЩЖ без ТХ (37,2% против 54,7%, Р &lt; 0,001). Не было статистически значимых различий Mts в латеральные лимфатические узлы (ЛЛУ) (Р = 0,656). Mts в лимфатические узлы (ЛУ) шеи были гистологически подтверждены у 127 (45,8%) пациентов с ПКЩЖ на фоне ТХ, включая 103 с Mts в ЦЛУ и 24 ЛЛУ. Не было выявлено существенных различий между Mts в латеральные ЛУ на фоне ТХ и классическими случаями МПКЩЖ; на фоне ТХ наблюдалось значительное снижение риска Mts в ЦЛУ по сравнению со случаями с МПКЩЖ (35,7% против 72,4% соответственно, Р &lt; 0,001). Уровень антител к тиреоидной пероксидазе (АТ-ТПО) &gt; 140 МЕ/мл был установлен как наиболее чувствительный и специфичный уровень для прогнозирования МПКЩЖ на основе проведенного исследования. Антитела к АТ-ТПО, возраст, размер опухоли и мультифокальная форма опухоли продемонстрировали способность прогнозировать Mts в ЦЛУ у пациентов с ПКЩЖ на фоне ТХ с вероятностью 81,1% на основе многомерной модели. ТХ был связан с повышенной распространенностью мультифокальной опухоли с инвазией в капсулу железы. Напротив, на фоне ТХ снижение риска и метастазирования в ЦЛУ у пациентов с ПКЩЖ и МПКЩЖ указывало на потенциальный защитный эффект. Мы обнаружили, что прогностическая модель применима для прогнозирования мультифокальности опухоли и метастазирования в ЦЛУ у пациентов с ПКЩЖ на фоне ТХ.</p></abstract><trans-abstract xml:lang="en"><p>The aim of this work was to study the risk factors for metastasis to the central and lateral neck lymph nodes in papillary thyroid carcinoma (PTC) and multifocal papillary thyroid carcinoma (MPTC), especially in patients with Hashimoto’s thyroiditis (TH).Methods: A retrospective analysis of 763 patients after thyroidectomy with bilateral central lymphadenectomy (CLE) was performed at the interterritorial Center for Endocrine Surgery in Krasnodar during the period from October 2011 to October 2021. All patients had official histological diagnoses of TH. To identify risk factors for metastasis (Mts) to the lymph nodes of the neck, a multifactorial logistic regression analysis was performed.Results: In our study, 277 patients with SCLC and TC showed relatively low rates of Mts to the central lymph nodes (CLU) compared with patients with SCLC without TC (37.2 % vs. 54.7 %, P  140 IU / ml was established as the most sensitive and specific level for predicting MPCT based on the study. Antibodies to AT-TPO, age, tumor size, and multifocal tumor shape demonstrated the ability to predict Mts in the central nervous system in patients with PCT on the background of TC with a probability of 81.1 % based on a multidimensional model. TH was associated with an increased prevalence of multifocal tumor with invasion of the gland capsule.Conclusions: TH detection demonstrated the reduced risk of metastases to the CLN in patients with PCT and MPCT and indicated a potential protective effect. We found that the prognostic model is applicable for predicting a multifocal tumor and metastasis to the central nervous system in patients with PCT and TH.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>тиреодит Хашимото</kwd><kwd>мультифокальный папиллярный рак</kwd><kwd>папиллярная карцинома</kwd><kwd>центральная лимфаденэктомия</kwd><kwd>метастаз</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Hashimoto’s thyroiditis</kwd><kwd>multifocal papillary cancer</kwd><kwd>papillary carcinoma</kwd><kwd>central lymphadenectomy</kwd><kwd>metastasis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Cooper DS, Doherty GM, et al. American Thyroid Association Guidelines Taskforce on Thyroid N Differentiated Thyroid C. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167–1214.</mixed-citation><mixed-citation xml:lang="en">Cooper DS, Doherty GM, et al. American Thyroid Association Guidelines Taskforce on Thyroid N Differentiated Thyroid C. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167–1214.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kwak JY, Kim EK, Kim JK, et al. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. Head Neck 2010; 32:490–498.</mixed-citation><mixed-citation xml:lang="en">Kwak JY, Kim EK, Kim JK, et al. Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. Head Neck 2010; 32:490–498.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ahmed R, Al-Shaikh S, Akhtar M. Hashimoto thyroiditis: a century later. Adv Anat Pathol 2012; 19:181–186.</mixed-citation><mixed-citation xml:lang="en">Ahmed R, Al-Shaikh S, Akhtar M. Hashimoto thyroiditis: a century later. Adv Anat Pathol 2012; 19:181–186.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metabol 2013; 98:474–482.</mixed-citation><mixed-citation xml:lang="en">Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto’s thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metabol 2013; 98:474–482.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Fugazzola L, Colombo C, Perrino M, et al. Papillary thyroid carcinoma and inflammation. Frontiers Endocrinol 2011; 2:88.</mixed-citation><mixed-citation xml:lang="en">Fugazzola L, Colombo C, Perrino M, et al. Papillary thyroid carcinoma and inflammation. Frontiers Endocrinol 2011; 2:88.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 2013; 168:343–349.</mixed-citation><mixed-citation xml:lang="en">Lee JH, Kim Y, Choi JW, et al. The association between papillary thyroid carcinoma and histologically proven Hashimoto’s thyroiditis: a meta-analysis. Eur J Endocrinol 2013; 168:343–349.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol 2009; 71:581–586.]</mixed-citation><mixed-citation xml:lang="en">Kim EY, Kim WG, Kim WB, et al. Coexistence of chronic lymphocytic thyroiditis is associated with lower recurrence rates in patients with papillary thyroid carcinoma. Clin Endocrinol 2009; 71:581–586.]</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Liu Y, Lv HJ, Zhang SQ, Shi BY, Sun YS. The Impact of Coexistent Hashimoto’s Thyroiditis on Central Compartment Lymph Node Metastasis in Papillary Thyroid Carcinoma. Front Endocrinol (2021) 12:772071:772071. doi: 10.3389/fendo. 2021.772071</mixed-citation><mixed-citation xml:lang="en">Liu Y, Lv HJ, Zhang SQ, Shi BY, Sun YS. The Impact of Coexistent Hashimoto’s Thyroiditis on Central Compartment Lymph Node Metastasis in Papillary Thyroid Carcinoma. Front Endocrinol (2021) 12:772071:772071. doi: 10.3389/fendo. 2021.772071</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Schindler AM, van Melle G, Evequoz B, et al. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991; 68:324–330.</mixed-citation><mixed-citation xml:lang="en">Schindler AM, van Melle G, Evequoz B, et al. Prognostic factors in papillary carcinoma of the thyroid. Cancer 1991; 68:324–330.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Anil C, Goksel S, Gursoy A. Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 2010; 20:601–606.</mixed-citation><mixed-citation xml:lang="en">Anil C, Goksel S, Gursoy A. Hashimoto’s thyroiditis is not associated with increased risk of thyroid cancer in patients with thyroid nodules: a single-center prospective study. Thyroid 2010; 20:601–606.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Bircan HY, Koc B, Akarsu C, et al. Is Hashimoto’s thyroiditis a prognostic factor for thyroid papillary microcarcinoma? Eur Rev Med Pharmacol Sci 2014; 18:1910–1915.</mixed-citation><mixed-citation xml:lang="en">Bircan HY, Koc B, Akarsu C, et al. Is Hashimoto’s thyroiditis a prognostic factor for thyroid papillary microcarcinoma? Eur Rev Med Pharmacol Sci 2014; 18:1910–1915.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg 2005; 71:874–878.]</mixed-citation><mixed-citation xml:lang="en">Cipolla C, Sandonato L, Graceffa G, et al. Hashimoto thyroiditis coexistent with papillary thyroid carcinoma. Am Surg 2005; 71:874–878.]</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015; 47:127–141.</mixed-citation><mixed-citation xml:lang="en">Jung KW, Won YJ, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. Cancer Res Treat 2015; 47:127–141.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955; 70:291–297.</mixed-citation><mixed-citation xml:lang="en">Dailey ME, Lindsay S, Skahen R. Relation of thyroid neoplasms to Hashimoto disease of the thyroid gland. AMA Arch Surg 1955; 70:291–297.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Jayaprakash K, Kishanprasad H, Hegde P, et al. Hashimotos thyroiditis with coexistent papillary carcinoma and non-Hodgkin lymphoma-thyroid. Ann Med Health Sci Res 2014; 4:268–270.</mixed-citation><mixed-citation xml:lang="en">Jayaprakash K, Kishanprasad H, Hegde P, et al. Hashimotos thyroiditis with coexistent papillary carcinoma and non-Hodgkin lymphoma-thyroid. Ann Med Health Sci Res 2014; 4:268–270.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Mazeh H, Samet Y, Hochstein D, et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011; 201:770–775.</mixed-citation><mixed-citation xml:lang="en">Mazeh H, Samet Y, Hochstein D, et al. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. Am J Surg 2011; 201:770–775.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang Y, Dai J, Wu T, et al. The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 2014; 140:1021–1026.</mixed-citation><mixed-citation xml:lang="en">Zhang Y, Dai J, Wu T, et al. The study of the coexistence of Hashimoto’s thyroiditis with papillary thyroid carcinoma. J Cancer Res Clin Oncol 2014; 140:1021–1026.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Ito Y, Miyauchi A. Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol 2015; 27:15–20.</mixed-citation><mixed-citation xml:lang="en">Ito Y, Miyauchi A. Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol 2015; 27:15–20.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Podnos YD, Smith D, Wagman LD, et al. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71:731–734.</mixed-citation><mixed-citation xml:lang="en">Podnos YD, Smith D, Wagman LD, et al. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005; 71:731–734.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">. Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 2011; 254:653–660.</mixed-citation><mixed-citation xml:lang="en">. Yu XM, Wan Y, Sippel RS, et al. Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg 2011; 254:653–660.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Vrachimis A, Gerss J, Stoyke M, et al. No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer. Clin Endocrinol 2014; 80:911–917.</mixed-citation><mixed-citation xml:lang="en">Vrachimis A, Gerss J, Stoyke M, et al. No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer. Clin Endocrinol 2014; 80:911–917.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. Ann Surg Oncol 2015; 22:125–131.</mixed-citation><mixed-citation xml:lang="en">Kim KJ, Kim SM, Lee YS, et al. Prognostic significance of tumor multifocality in papillary thyroid carcinoma and its relationship with primary tumor size: a retrospective study of 2,309 consecutive patients. Ann Surg Oncol 2015; 22:125–131.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Hyun SM, Song HY, Kim SY, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. Ann Surg Oncol 2012; 19:591–596.</mixed-citation><mixed-citation xml:lang="en">Hyun SM, Song HY, Kim SY, et al. Impact of combined prophylactic unilateral central neck dissection and hemithyroidectomy in patients with papillary thyroid microcarcinoma. Ann Surg Oncol 2012; 19:591–596.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22:1144–1152.</mixed-citation><mixed-citation xml:lang="en">Randolph GW, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid 2012; 22:1144–1152.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Kurukahvecioglu O, Taneri F, Yuksel O, et al. Total thyroidectomy for the treatment of Hashimoto’s thyroiditis coexisting with papillary thyroid carcinoma. Adv Ther 2007; 24:510–516.</mixed-citation><mixed-citation xml:lang="en">Kurukahvecioglu O, Taneri F, Yuksel O, et al. Total thyroidectomy for the treatment of Hashimoto’s thyroiditis coexisting with papillary thyroid carcinoma. Adv Ther 2007; 24:510–516.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 2008; 150:49–52.</mixed-citation><mixed-citation xml:lang="en">Repplinger D, Bargren A, Zhang YW, et al. Is Hashimoto’s thyroiditis a risk factor for papillary thyroid cancer? J Surg Res 2008; 150:49–52.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Jin S, Sugitani I. Narrative Review of Management of Thyroid Surgery Complications. Gland Surg (2021) 10 (3):1135–46. doi: 10.21037/gs-20-859</mixed-citation><mixed-citation xml:lang="en">Jin S, Sugitani I. Narrative Review of Management of Thyroid Surgery Complications. Gland Surg (2021) 10 (3):1135–46. doi: 10.21037/gs-20-859</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Consorti F, Loponte M, Milazzo F, et al. Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res 2010; 45:333–337.</mixed-citation><mixed-citation xml:lang="en">Consorti F, Loponte M, Milazzo F, et al. Risk of malignancy from thyroid nodular disease as an element of clinical management of patients with Hashimoto’s thyroiditis. Eur Surg Res 2010; 45:333–337.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001; 25:632–637.</mixed-citation><mixed-citation xml:lang="en">Kebebew E, Treseler PA, Ituarte PH, et al. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001; 25:632–637.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Kim HS, Choi YJ, Yun JS. Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis. Endocr Pathol 2010; 21:149–153.</mixed-citation><mixed-citation xml:lang="en">Kim HS, Choi YJ, Yun JS. Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis. Endocr Pathol 2010; 21:149–153.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28:742–762.</mixed-citation><mixed-citation xml:lang="en">Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28:742–762.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007; 148:936–941.]</mixed-citation><mixed-citation xml:lang="en">Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007; 148:936–941.]</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068–1081.</mixed-citation><mixed-citation xml:lang="en">Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 2005; 115:1068–1081.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Bozec A, Lassalle S, Hofman V, et al. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 2010; 17:3449–3461.</mixed-citation><mixed-citation xml:lang="en">Bozec A, Lassalle S, Hofman V, et al. The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 2010; 17:3449–3461.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zeng RC, Jin LP, Chen ED, et al. Potential relationship between Hashimoto’s thyroiditis and BRAF mutation status in papillary thyroid cancer. Head Neck 2015.</mixed-citation><mixed-citation xml:lang="en">Zeng RC, Jin LP, Chen ED, et al. Potential relationship between Hashimoto’s thyroiditis and BRAF mutation status in papillary thyroid cancer. Head Neck 2015.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006; 15:136–143.</mixed-citation><mixed-citation xml:lang="en">Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol 2006; 15:136–143.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246:466–470.</mixed-citation><mixed-citation xml:lang="en">Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007; 246:466–470.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Jiang LH, Yin KX, Wen QL, Chen C, Tan Z. Predictive Risk-Scoring Model for Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma. Sci Rep (2020) 10 (1):710. doi: 10.1038/s41598-019-55991-1</mixed-citation><mixed-citation xml:lang="en">Jiang LH, Yin KX, Wen QL, Chen C, Tan Z. Predictive Risk-Scoring Model for Central Lymph Node Metastasis and Predictors of Recurrence in Papillary Thyroid Carcinoma. Sci Rep (2020) 10 (1):710. doi: 10.1038/s41598-019-55991-1</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Oler G, Camacho CP, Hojaij FC, et al. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 2008; 14:4735–4742.</mixed-citation><mixed-citation xml:lang="en">Oler G, Camacho CP, Hojaij FC, et al. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis. Clin Cancer Res 2008; 14:4735–4742.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metabol 2014; 25:656–664.</mixed-citation><mixed-citation xml:lang="en">Ehlers M, Schott M. Hashimoto’s thyroiditis and papillary thyroid cancer: are they immunologically linked? Trends Endocrinol Metabol 2014; 25:656–664.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Cunha LL, Morari EC, Guihen AC, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol 2012; 77:918–925.</mixed-citation><mixed-citation xml:lang="en">Cunha LL, Morari EC, Guihen AC, et al. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. Clin Endocrinol 2012; 77:918–925.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
